



## **RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference**

May 20, 2021

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 3:00 pm Eastern Time.

To access the live webcast and subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at <https://investors.rapt.com/events-and-presentations>.

### **About RAPT Therapeutics, Inc.**

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

### **RAPT Media Contact:**

Aljanae Reynolds  
[areynolds@wheelhousesa.com](mailto:areynolds@wheelhousesa.com)

### **RAPT Investor Contact:**

Sylvia Wheeler  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)